Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Garmin Ltd. (NASDAQ: GRMN) shares spiked 4.76 percent to close at $40.28 a share Wednesday. The stock traded between $38.57 and $40.94 on volume of 2.96 million shares traded. Analysts at Goldman Sachs have recently upgraded the company’s rating to “neutral” from “sell”.
Find out more about Garmin including full access to the free equity report at:
GlaxoSmithKline plc (NYSE: GSK) shares closed at $51.86 a share Wednesday. The stock traded between $51.68 and $52.20 on volume of 2.20 million shares traded. Analysts at Cowen have recently upgraded the company’s rating to “outperform” from “market perform”. Shares of GlaxoSmithKline have gained approximately 19.0 percent year-to-date.
Find out more about GlaxoSmithKline including full access to the free equity report at:
Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) shares increased 4.43 percent to close at $67.83 a share Wednesday. The stock traded between $66.91 and $68.89 on volume of 1.79 million shares traded. Analysts at Bank of America Merrill Lynch have recently upgraded the company’s rating to “buy” from “neutral”. Shares of Questcor Pharmaceuticals have gained approximately 150.0 percent year-to-date.
Find out more about Questcor Pharmaceuticals including full access to the free equity report at:
Ubiquiti Networks Inc. (NASDAQ: UBNT) shares increased 1.20 percent to close at $29.56 a share Wednesday. The stock traded between $28.68 and $30.10 on volume of 511,222 shares traded. Analysts at Craig-Hallum have recently initiated coverage on the company with a “buy” rating and a price target of $42.00. Shares of Ubiquiti Networks have gained approximately 140.0 percent year-to-date.
Find out more about Ubiquiti Networks including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...